3 Dirt-Cheap Cannabis Stocks That Just Might Triple by 2023

Marijuana is seen as one of the biggest growth markets around, even if many of its leading stocks have fallen far short of expectations. That just means the field is still wide open and anyone can…

gain an advantage to come out ahead. Once the cannabis industry finally does take off we may see all boats lifted by the rising tide, but Planet 13 Holdings (OTC:PLNH.F)Trulieve Cannabis (OTC:TCNNF), and the AdvisorShares Pure US Cannabis ETF (NYSEMKT:MSOS) may have already tripled in value by then.

Planet 13 has a clear (and short) path to multiplying in value

Alex Carchidi (Planet 13 Holdings): If you’ve ever visited the Las Vegas Strip, you’ve probably seen or even experienced Planet 13’s flagship cannabis superstore, where more than a million tourists flocked to buy marijuana in 2019. Right now, Planet 13’s shares go around $5.19, but at the rate the company is growing, it could be worth as much as $20 in the next few years.

In terms of its valuation, Planet 13’s price-to-sales ratio is nearly 11, and its locations in Nevada brought in around $70.49 million in 2020. The legal cannabis industry’s average P/S ratio is 24.4, so Planet 13 looks quite cheap in comparison.

By 2023, management estimates it will make $130 million in annual revenue from its stores in Nevada alone. If the stock traded at the industry’s average P/S ratio at that point in time, its shares would be worth around $16.22, which is more than triple its current price.

And that’s before taking into account the new income from its recently opened superstore in California, which will report its inflows for the first time in the next earnings report, which is scheduled for late August. Nor does it consider the company’s plans to open eight or more retail locations, which are expected to be in operation by 2025.

So, while there’s no guarantee that these new stores will bring in as much cash as its high-traffic location in Las Vegas, investors can still expect significant revenue growth as the company penetrates its new markets. And that additional income could easily lead to the stock tripling in the next couple of years when combined with what’s already expected from its existing stores.

Slow and steady wins the race

Rich Duprey (Trulieve Cannabis): Multi-state operators like Trulieve Cannabis have an extra burden to carry that other marijuana companies do not. Because cannabis remains a Schedule 1 drug under the Controlled Substances Act, MSOs operating in states where marijuana is legal are unable to deduct normal business expenses like employee salaries, marketing, and health insurance premiums. That’s made it difficult for many to operate profitably, but Trulieve has still managed to generate adjusted profits for four consecutive quarters.

Federal legalization would eliminate such quirks of the law, including opening up financing and allowing MSOs to establish relationships with banks instead of having to operate in cash. They would also be able to list their stocks on a major exchange.

Trulieve is narrowly focused in Florida where it is the state’s largest licensed medical marijuana provider with the most locations and the greatest volume. However, it is working on replicating its successful strategy elsewhere. It has licenses to operate in six other states, and was just granted a license to operate in a seventh, Georgia.

Revenue is rapidly rising, up 11% sequentially in the second quarter and 78% year over year, while adjusted EBITDA is 69% higher over the first six months of 2021. While it is steadily growing organically, it is not above making strategic acquisitions, such as its recent $2.1 billion purchase of Harvest Health & Recreation.

Despite this healthy expansion…

Continue reading at THE MOTLEY FOOL